Eli Lilly is hoping new data from its Taltz (ixekizumab) could give it another potentially lucrative indication and put pressure on Novartis’ rival IL-17a drug, Cosentyx. Already approved in ...
Cosentyx also faces direct competition from rival IL-17 drugs such as Lilly's Taltz (ixekizumab) and Valeant’s Siliq (brodalumab). Novartis’ chief medical officer, Vas Narasimhan, said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback